Akèy › Limfòm selil-T perifèrik
Etid klinik pou Limfòm selil-T perifèrik ap rekrite nan Etazini
19 etid pou Limfòm selil-T perifèrik ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- Houston, TX9 etid
- New York City, NY6 etid
- Baldwin Park, CA5 etid
- Boston, MA5 etid
- Philadelphia, PA4 etid
- Atlanta, GA4 etid
- Columbus, OH3 etid
- Ann Arbor, MI3 etid
- Aurora, CO3 etid
Pa eta
- Colorado3 etid
- Florid4 etid
- Georgia4 etid
- Kalifòni8 etid
- Massachusetts5 etid
- Michigan5 etid
- New Jersey3 etid
- New York7 etid
- Ohio5 etid
- Pennsylvania6 etid
- Texas10 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Ap rekriteEtid obsèvasyon
Laj 0 a 38 · Tout sèks · Mizajou Oct 1, 2026 · NCT06131801A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT07192471A Phase II, Single-center, Single-arm Study Evaluating the Safety and Efficacy of Golidocitinib in the Management of Newly Diagnosed Peripheral T Cell Lymphoma Patients (GOLDEN Study) and Correlative Study
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06630091Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06561048CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma
Ap rekriteFaz 2
Laj 18 a 99 · Tout sèks · Mizajou Sep 24, 2026 · NCT04083495A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 15, 2026 · NCT07195916AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
Ap rekriteFaz 1/2
Laj 12 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT06137144Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma
Ap rekriteFaz 1 bonè
Laj 1 a 31 · Tout sèks · Mizajou Aug 18, 2026 · NCT03719105Sample Collection for Ongoing Research and Product Evaluation Study - Non-Hodgkin Lymphoma (SCORE-NHL)
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Aug 6, 2026 · NCT07750886A Pilot of a Microdevice For In Situ Candidate Drug Screening in Cutaneous Lesions of T-Cell Lymphoma
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Jul 27, 2026 · NCT04045470To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Jul 22, 2026 · NCT06072131Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas
Ap rekriteFaz 1
Laj 12 a 75 · Tout sèks · Mizajou Jul 20, 2026 · NCT06176690Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 1, 2026 · NCT06508463Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jun 24, 2026 · NCT04068597Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jun 11, 2026 · NCT05313243Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Apr 15, 2026 · NCT07356245Amping up With PemJAK
Ap rekriteFaz 2
Laj 18 a 95 · Tout sèks · Mizajou Dec 16, 2025 · NCT07283822Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2025 · NCT04234048Prospective Observational International Registry of Patients With Newly Diagnosed Peripheral T Cell Lymphoma.
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou May 6, 2025 · NCT03964480Sous ClinicalTrials.gov, done yo ranmase Oct 2, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.